Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of E5501 plus standard of care in adults with chronic immune thrombocytopenia
NL-OMON37708Phase 3Withdrawn
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing E5501 plus standard of care, Placebo plus standard of care and Open-label extension E5501 (3 arms). Primary endpoint: Durable platelet response over 6 months. Planned start Aug 2012; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON37708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37708.